Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Calcif Tissue Int ; 82(3): 221-8, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18265928

ABSTRACT

Anabolic skeletal agents have recently broadened the therapeutic options for osteoporosis by directly stimulating bone formation and improving bone turnover, bone density, bone size, and bone microarchitecture. We recently demonstrated that two new L: -carnitine derivatives, L: -carnitine fumarate (LC) and isovaleryl-L: -carnitine fumarate (Iso-V-LC), stimulated osteoblast proliferation and differentiation. We here investigated, by histomorphometry in a mouse model of osteoporosis, the impact of these compounds on the repair of trabecular bone and the osteoblast involvement in this process. Fifty-nine inbred adult female CD1 mice in pregnancy were assigned to four treatment groups: (1) controls, mice fed a standard normocalcemic pre- and postpartal diet; (2) Hypo, mice fed a low-calcium isocaloric prepartal diet and a standard postpartal diet; (3) LC, mice fed a group 2-type diet supplemented post-partum with LC; (4) Iso-V-LC, mice fed a group 2-type diet supplemented post-partum with Iso-V-LC. Bone volume/total volume ratio (BV/TV), bone perimeter, osteoblast surface/bone surface, and osteoblast number/bone surface were measured from sections of L3 and L4 vertebral bodies obtained from animals killed on the day of delivery (controls and Hypo) and on days 7, 14, and 21 after delivery (all groups). BV/TV and all osteoblast-based indexes were significantly higher in LC and Iso-V-LC than in Hypo mice at each time point, and Iso-V-LC at the end of the treatment attained levels observed in controls. In conclusion, Iso-V-LC and, to a lesser extent, LC accelerated the recovery of normal BV/TV level after a hypocalcemic diet.


Subject(s)
Carnitine/pharmacology , Osteoporosis/drug therapy , Animals , Calcification, Physiologic/drug effects , Calcification, Physiologic/physiology , Calcium/metabolism , Calcium, Dietary/administration & dosage , Carnitine/analogs & derivatives , Cell Count , Cell Proliferation/drug effects , Disease Models, Animal , Drug Therapy, Combination , Female , Fumarates , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/metabolism , Lumbar Vertebrae/pathology , Mice , Mice, Inbred Strains , Osteoblasts/drug effects , Osteoblasts/physiology , Osteoporosis/pathology , Pregnancy
2.
Calcif Tissue Int ; 76(6): 458-65, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15906015

ABSTRACT

Age-related bone loss is characterized by decreased osteoblast activity, possibly related to the reduction of energy production. Carnitine promotes energy availability and its concentration declines with age; Therefore, two Carnitine derivatives, L-carnitine fumarate (LC) and isovaleryl L-carnitine fumarate (Iso-V-LC), have been tested on several parameters of human osteoblasts in vitro. Both compounds significantly increased osteoblast activity, but the new compound Iso-V-LC was more efficient than LC at lower concentrations. They both significantly enhanced cell proliferation, [3H]-proline incorporation and the expression of collagen type I (COLLI), and the bone sialoproteins (BSPs) and osteopontin (OPN). The percentage of alkaline phosphatase (ALP)-positive cells and the secretion of osteocalcin were not modified by LC and Iso-V-LC. Both molecules increased the formation of mineralized nodules, but Iso-V-LC reached the maximum effect at a concentration 10-fold lower than that of LC. Furthermore, we showed that insulin-like growth factor (IGF)-I and IGF-II mRNA levels were not modified by the treatment. However, the two compounds induced an increase of insulin-like growth factor binding protein (IGFBP)-3 and a decrease of IGFBP-5 in both osteoblast lysates and the extracellular matrix (ECM). In conclusion these data suggest that carnitine and, in particular, its new derivative, Iso-V-LC supplementation in the elderly may stimulate osteoblast activity and decrease age-related bone loss.


Subject(s)
Carnitine/analogs & derivatives , Carnitine/pharmacology , Osteoblasts/cytology , Osteoblasts/drug effects , Alkaline Phosphatase/drug effects , Alkaline Phosphatase/metabolism , Blotting, Western , Calcification, Physiologic/drug effects , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Collagen Type I/drug effects , Collagen Type I/metabolism , Humans , In Vitro Techniques , Osteocalcin/drug effects , Osteocalcin/metabolism , Osteopontin , Receptors, Somatomedin/drug effects , Receptors, Somatomedin/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sialoglycoproteins/drug effects , Sialoglycoproteins/metabolism , Somatomedins/drug effects , Somatomedins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...